EcoDrugPlus

Cytochrome P450, Family 17, Subfamily A, Polypeptide 1

Ensembl ID : ENSOMYG00000004006
Gene Symbol: CYP17A1
2 Cross references
210 Possible Orthologues:

Cytochrome P450, Family 19, Subfamily A, Polypeptide 1a

Ensembl ID : ENSOMYG00000032044
Gene Symbol: CYP19A1A
1 Cross references
244 Possible Orthologues:

Cytochrome P450, Family 19, Subfamily A, Polypeptide 1a

Ensembl ID : ENSOMYG00000020944
Gene Symbol: CYP19A1A
1 Cross references
246 Possible Orthologues:

Cytochrome P450, Family 26, Subfamily A, Polypeptide 1

Ensembl ID : ENSOMYG00000071019
Gene Symbol: CYP26A1
1 Cross references
193 Possible Orthologues:

Cytochrome P450, Family 26, Subfamily A, Polypeptide 1

Ensembl ID : ENSOMYG00000039042
Gene Symbol: CYP26A1
1 Cross references
193 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1a

Ensembl ID : ENSOMYG00000017758
Gene Symbol: DGAT1A
2 Cross references
184 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1a

Ensembl ID : ENSOMYG00000012689
Gene Symbol: DGAT1A
1 Cross references
184 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1b

Ensembl ID : ENSOMYG00000024210
Gene Symbol: DGAT1B
1 Cross references
187 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1b

Ensembl ID : ENSOMYG00000064075
Gene Symbol: DGAT1B
1 Cross references
187 Possible Orthologues:

Dihydroorotate Dehydrogenase

Ensembl ID : ENSOMYG00000042076
Gene Symbol: DHODH
1 Cross references
167 Possible Orthologues:

Dihydroorotate Dehydrogenase

Ensembl ID : ENSOMYG00000029214
Gene Symbol: DHODH
1 Cross references
167 Possible Orthologues:

Dihydropyrimidine Dehydrogenase

Ensembl ID : ENSOMYG00000020023
Gene Symbol: DPYD
1 Cross references
166 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).